EPS for Neovasc Inc. (NVCN) Expected At $-0.01

March 3, 2018 - By Hazel Jackson

 EPS for Neovasc Inc. (NVCN) Expected At $ 0.01

Analysts expect Neovasc Inc. (NASDAQ:NVCN) to report $-0.01 EPS on March, 22.They anticipate $0.48 EPS change or 102.13 % from last quarter’s $0.47 EPS. After having $-0.06 EPS previously, Neovasc Inc.’s analysts see -83.33 % EPS growth. The stock decreased 4.32% or $0.0092 during the last trading session, reaching $0.2036. About 11.30M shares traded or 336.55% up from the average. Neovasc Inc. (NASDAQ:NVCN) has declined 19.02% since March 3, 2017 and is downtrending. It has underperformed by 35.72% the S&P500.

Neovasc Inc. (NASDAQ:NVCN) Ratings Coverage

Among 3 analysts covering Neovasc (NASDAQ:NVCN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Neovasc had 7 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Neovasc Inc. (NASDAQ:NVCN) earned “Buy” rating by Zacks on Wednesday, August 12. The firm earned “Market Outperform” rating on Wednesday, October 7 by JMP Securities. The firm has “Buy” rating given on Tuesday, August 25 by Canaccord Genuity. On Friday, May 20 the stock rating was downgraded by Ladenburg Thalmann to “Neutral”. The firm earned “Buy” rating on Thursday, December 10 by Ladenburg Thalmann. The firm earned “Hold” rating on Wednesday, August 26 by Zacks.

Neovasc Inc., a specialty medical device company, develops, makes, and markets cardiovascular devices worldwide. The company has market cap of $20.80 million. The Company’s products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. It has a 0.8 P/E ratio. The firm also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart valves for industry partners and other customers.

More news for Neovasc Inc. (NASDAQ:NVCN) were recently published by: Seekingalpha.com, which released: “Is This Investment Too Risky?” on April 18, 2017. Prnewswire.com‘s article titled: “Fred Colen Appointed Chief Executive Officer of Neovasc Inc.” and published on January 22, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.